Identification and screening of triptolide target molecules
AssigneePharmagenesis, Inc.
InventorsJohn M. Fidler, John H. Musser
Life of this patent
Estimating the term…
Abstract
The identification of triptolide target molecules is described. Also described are methods of screening triptolide-related compounds for binding to these molecules, including screening for enhanced and/or selective binding, and expression analysis of the target molecules in normal and in diseased tissue.
Claims2
A method of screening triptolide or a triptolide analog selected from the group consisting of 2-hydroxytriptolide, 16-hydroxytriptolide (tripdiolide), 14-methyltriptolide, triptolide 14-tert-butyl carbonate, 14-deoxy-14α-fluoro triptolide, triptolide 14-(α-dimethylamino)acetate, triptolide 14-succinate, triptolide 14-γ-benzyl-N-benzyloxycarbonyl-(L)-glutamate ester, triptolide 14-N-t-butoxycarbonyl-α-t-butyl-L-glutamate ester, triptolide 14-β-benzyl-N-benzyloxycarbonyl-(L)-aspartate triptolide ester, triptolide 14-α-benzyl-N-benzyloxycarbonyl-D-glutamate ester, 14-isoglutamyl ester, 14-ethyl carbamate, 14-phenyl carbamate, 14-dimethylaminoethyl carbamate, N-methylpiperazinecarbonyl (carbamate), 14-ethyl carbonate, 14-phenyl carbonate, 14-ethoxyethyl carbonate, 14-methoxycarbonylmethyl carbonate, 14-(R)-α-methyl-tert-butoxycarbonylmethyl carbonate, 14-dimethylaminoethyl carbonate, 14-hydroxycarbonylmethyl carbonate, 5-α-hydroxy triptolide, 19-methyl triptolide, 18-deoxo-19-dehydro-18-benzoyloxy-19-benzoyl triptolide, 12-tosloxy-13-hydroxy triptolide and 18-glutaryl furanoid triptolide for binding to a triptolide target molecule and subsequent selection for further testing of its ability to influence activity of the target molecule, comprising:
- (a) identifying a binding interaction between the tripolide analog and a triptolide target molecule selected from the group consisting of:
- HSP 90 β (designated PG771),
- L-plastin (designated PG772),
- 14-3-3 ε (designated PG773),
- Thioredoxin Reductase (designated PG774),
- Protein Disulfide Isomerase (designated PG775),
- Phosphatidyl Inositol 3 Kinase (Class II) (designated PG776),
- Hypothetical Protein FLJ20297 (designated PG777),
- Vimentin (designated PG778),
- Eukaryotic Translation Elongation Factor 2 (EEF2) (designated PG786),
- Hypothetical Protein GI 14758649 (designated PG787),
- Hypothetical Protein GI 11277141 (designated PG788),
- Human Serine/Threonine Protein Phosphatase 2A (130 KDa regulatory subunit PP2A) (designated PG789), and
- Hypothetical Protein GI 7705346 (designated PG790);
- and
- (b) selecting the triptolide or triptolide analog for said further testing of its ability to influence the activity of the target molecule based on the binding of the triptolide or triptolide analog to the target.
Dependencies are inferred from the claim text.